This screening model, which prevents exon7 exclusion in the SMN2 gene, has been widely used, and several pharmacological compounds have been investigated for their splicing correction abilities in order to maintain the full length of SMN2 proteins for therapeutic strategies of SMA disease [12-14]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.